Selegiline


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Early parkinsonism
Adult: As conventional preparation: 10 mg daily, either as a single dose (in the morning) or in 2 divided doses of 5 mg (at breakfast and lunchtime). As oral lyophilisate tab: Initially, 1.25 mg daily.

Transdermal
Depression
Adult: Initially, 6 mg daily, may increase in increments of 3 mg/24 hr every 2 weeks. Max: 12 mg/24 hr. Patches should be changed every 24 hours and new patch is applied to a different site. (Patient on doses ≥9 mg/24 hr should restrict intake of tyramine-rich foods during and for 2 weeks after treatment discontinuation.
Elderly: ≥65 yr 6 mg/24 hr.
Cách dùng
Should be taken with food.
Chống chỉ định
Active duodenal or gastric ulcer. Concomitant use w/ serotonin agonists (e.g. sumatriptan, zolmitriptan), pethidine and other opioids, antidepressants (including TCAs, MAOIs, SSRIs, serotonin norepinephrine reuptake inhibitors), St John’s wort.
Thận trọng
Patient w/ uncontrolled HTN, angina, arrhythmias, psychosis, history of peptic ulcer and those at risk of orthostatic hypotension. Severe hepatic or renal impairment. Elderly. Pregnancy and lactation.
Tác dụng không mong muốn
Orthostatic hypotension, chest pain, headache, confusion, tremor, vertigo, dizziness, depression, psychosis, hallucinations, agitation, nausea, vomiting, diarrhoea, constipation, dry mouth, sore throat, difficulty in micturition, skin reactions, muscle cramps, back and joint pain, myopathy; insomnia, abnormal dreams; transient elevations in liver enzymes; mouth ulcers, stomatitis.
Thông tin tư vấn bệnh nhân
This drug may cause somnolence, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor BP, symptoms of parkinsonism, suicidal ideation, general mood and behaviour. Perform periodic skin examinations.
Quá liều
Symptoms: Ataxia, dizziness, tremor, irritability, pyrexia, convulsions, hypomania, psychosis, euphoria, resp depression, severe muscle spasms, hypotension, HTN, coma, extrapyramidal symptoms. Management: Symptomatic treatment.
Tương tác
May increase risk of hypertensive reactions w/ dopamine. May increase bioavailability w/ OCs or drugs for hormone replacement therapy.
Potentially Fatal: May cause severe serotonin syndrome w/ antidepressants (including TCAs, MAOIs, SSRIs, serotonin norepinephrine reuptake inhibitors), serotonin agonists (e.g. sumatriptan, zolmitriptan). May cause resp depression and hypotension w/ pethidine and other opioids.
Tương tác với thức ăn
May cause severe serotonin syndrome w/ St John’s wort. May cause hypertensive crisis w/ tyramine-rich food and beverages. Increased sedative effects w/ alcohol.
Ảnh hưởng đến kết quả xét nghiệm
May cause false-positive reaction w/ urine detection of amphetamine/methamphetamine.
Tác dụng
Description:
Mechanism of Action: Selegiline increases dopaminergic activity by intervening w/ the reuptake of dopamine at the synapse. It also irreversibly inhibits monoamine oxidase (MAO)-B which is involved in the metabolism of dopamine in the brain.
Onset: W/in 1 hr (oral).
Duration: 24-72 hr (oral).
Pharmacokinetics:
Absorption: Readily absorbed from the GI tract. Bioavailability: Approx 10%. Time to peak plasma concentration: 30 min (oral conventional preparation).
Distribution: Rapidly distributed throughout the body; crosses the blood-brain barrier. Plasma protein binding: Up to 94%.
Metabolism: Undergoes extensive first-pass metabolism; converted to at least 5 metabolites including l-(-)-desmethylselegiline (norselegiline), l-(-)-N-methylamfetamine and l-(-)-amfetamine.
Excretion: Mainly via urine, as metabolites; faeces (approx 15%). Elimination half-life: 10 hr (oral); 18-25 hr (transdermal).
Đặc tính

Chemical Structure Image
Selegiline

Source: National Center for Biotechnology Information. PubChem Database. Selegiline, CID=26757, https://pubchem.ncbi.nlm.nih.gov/compound/Selegiline (accessed on Jan. 23, 2020)

Bảo quản
Store between 20-25°C.
Phân loại MIMS
Thuốc trị bệnh Parkinson
Phân loại ATC
N04BD01 - selegiline ; Belongs to the class of dopaminergic agents, monoamine oxidase B inhibitors. Used in the management of Parkinson's disease.
Tài liệu tham khảo
Anon. Selegiline. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/02/2016.

Buckingham R (ed). Selegiline Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/02/2016.

EMSAM patch (Mylan Specialty). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 04/02/2016.

Joint Formulary Committee. Selegiline Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/02/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Selegiline Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 04/02/2016.

Preston CL (ed). Selegiline + Oxycodone. Stockley’s Drug Interactions [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/02/2016.

Preston CL (ed). Selegiline + Pethidine. Stockley’s Drug Interactions [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/02/2016.

Preston CL (ed). Zolmitriptan + Selegiline. Stockley’s Drug Interactions [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/02/2016.

Selegiline Hydrochloride Capsule (Apotex Corp.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 04/02/2016.

Zelapar (Selegiline Hydrochloride) Orally Disintegrating Tablets. U.S. FDA. https://www.fda.gov/. Accessed 04/02/2016.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Selegiline từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Cognitive
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in